Time-to-progression after frontline chemoimmunotherapy for chronic lymphocytic leukemia: an independently validated retrospective cohort study

BACKGROUND: Because frontline treatment with FCR unequivocally improves progression-free and overall survival in CLL patients, it has become a “gold standard” for chemoimmunotherapy regimens. Follow-up studies show that a subset of generally young, physically-fit patients with mutated IGHV genes and...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Lancet Oncol
Autors principals: Herling, Carmen D., Coombes, Kevin R., Benner, Axel, Bloehdorn, Johannes, Barron, Lynn L., Abrams, Zachary B., Majewski, Tadeusz, Bondaruk, Jolanta E., Bahlo, Jasmin, Fischer, Kirsten, Hallek, Michael, Stilgenbauer, Stephan, Czerniak, Bogdan A., Oakes, Christopher, Ferrajoli, Alessandra, Keating, Michael J., Abruzzo, Lynne V.
Format: Artigo
Idioma:Inglês
Publicat: 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7147008/
https://ncbi.nlm.nih.gov/pubmed/31582354
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(19)30503-0
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars